Aclaris Therapeutics, Inc. (ACRS)
$
1.84
+0.02 (1.09%)
Key metrics
Financial statements
Free cash flow per share
-0.3741
Market cap
199.3 Million
Price to sales ratio
11.8727
Debt to equity
0.0180
Current ratio
3.8825
Income quality
0.0742
Average inventory
0
ROE
-0.9592
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates for immune-inflammatory diseases in the United States. The weighted average number of shares outstanding is 77,296,665.00 highlighting the company's shareholder base. Aclaris operates through two segments: Therapeutics and Contract Research. The Therapeutics segment identifies and develops therapies to meet significant unmet needs in immuno-inflammatory diseases, while the Contract Research segment provides laboratory services. The company reported a net loss of -$132,065,000.00 indicating challenges in its operations. Key products include Zunsemetinib, an MK2 inhibitor targeting moderate to severe rheumatoid and psoriatic arthritis, and ATI-1777, a soft JAK 1/3 inhibitor aimed at moderate to severe atopic dermatitis. Additionally, the company is developing ATI-2138, an ITK/TXK/JAK3 inhibitor for T cell-mediated autoimmune diseases, as well as a Gut-Biased Program for inflammatory bowel disease and ATI-2231, an MK2 inhibitor targeting pancreatic and metastatic breast cancer. The operating income ratio is -7.58 showcasing the company’s operational profitability margin, while the EBITDA sits at -$51,720,000.00 a key measure of operational profitability. Earnings per share (EPS) is reported at -$1.71 reflecting the company's profitability on a per-share basis. In the broader market context, the stock is affordable at $1.58 making it suitable for budget-conscious investors. It has a high average trading volume of 1,116,934.00 indicating strong liquidity within the market. With a market capitalization of $199,330,880.00 Aclaris is classified as a small-cap player, positioning itself as a key contributor in the Medical - Diagnostics & Research industry that significantly impacts the overall market landscape. Moreover, it belongs to the Healthcare sector, where it drives innovation and growth. The company’s strategic focus on addressing unmet medical needs underscores its role in advancing therapeutic options for patients suffering from chronic conditions.
Is Aclaris Therapeutics, Inc. (ACRS) a good investment?
Investing in Aclaris Therapeutics, Inc. (ACRS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Aclaris Therapeutics, Inc. (ACRS)'s stock forecast?
Analysts predict Aclaris Therapeutics, Inc. stock to fluctuate between $1.05 (low) and $5.17 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aclaris Therapeutics, Inc.'s market capitalization?
As of 2025-08-29, Aclaris Therapeutics, Inc.'s market cap is $199,330,880, based on 108,332,000 outstanding shares.
How does Aclaris Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Aclaris Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aclaris Therapeutics, Inc. (ACRS) stock?
To buy Aclaris Therapeutics, Inc. (ACRS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACRS. Place an order (Market, Limit, etc.).
What is the best time to invest in Aclaris Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Aclaris Therapeutics, Inc. perform in the last earnings report?
Revenue: $18,720,000 | EPS: -$1.71 | Growth: 34.65%.
Where can I find Aclaris Therapeutics, Inc.'s investor relations reports?
Visit https://www.aclaristx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aclaris Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aclaris Therapeutics, Inc. stock?
All-time high: $19.97 (2021-09-27) | All-time low: $0.59 (2023-11-13).
What are the key trends affecting Aclaris Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
2 days ago
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Cantor Global Healthcare Conference in New York, NY.
zacks.com
22 days ago
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
globenewswire.com
23 days ago
- Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2025 and provided a corporate update.
zacks.com
a month ago
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com
a month ago
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of IT
globenewswire.com
a month ago
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D.
globenewswire.com
2 months ago
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization.
globenewswire.com
2 months ago
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference.
globenewswire.com
2 months ago
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody.
globenewswire.com
3 months ago
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June.
See all news
